{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:09:44Z","timestamp":1778713784014,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["\/2025\/338"],"award-info":[{"award-number":["\/2025\/338"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bcp.2026.117889","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:19:45Z","timestamp":1773188385000},"page":"117889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PMEPA1 promotes mTOR inhibitor resistance in triple-negative breast cancer: Targeting the TGF-\u03b2\/PMEPA1 axis as a therapeutic strategy to overcome resistance"],"prefix":"10.1016","volume":"249","author":[{"given":"MS.","family":"Chithra Pournami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biswajit","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Balaji","family":"Andugulpati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Ummanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.117889_b0005","doi-asserted-by":"crossref","unstructured":"R.L. Siegel, K.D. Miller, N.S. Wagle, A. Jemal, Cancer statistics, 2023, CA: a cancer journal for clinicians 73(1) (2023).","DOI":"10.3322\/caac.21763"},{"issue":"6797","key":"10.1016\/j.bcp.2026.117889_b0010","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.bcp.2026.117889_b0015","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.117889_b0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.bcp.2026.117889_b0025","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","article-title":"Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors","volume":"34","author":"LoRusso","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117889_b0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: a review","volume":"169","author":"Costa","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.bcp.2026.117889_b0035","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/bcp.12958","article-title":"The therapeutic potential of mTOR inhibitors in breast cancer","volume":"82","author":"Steelman","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117889_b0040","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/1878-0261.12078","article-title":"K\u2010Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines","volume":"11","author":"Yeung","year":"2017","journal-title":"Mol. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117889_b0045","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/bjc.2013.505","article-title":"PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K\/Akt activation","volume":"109","author":"Seront","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"23","key":"10.1016\/j.bcp.2026.117889_b0050","doi-asserted-by":"crossref","first-page":"19500","DOI":"10.18632\/oncotarget.3669","article-title":"Epithelial to mesenchymal transition is associated with rapamycin resistance","volume":"6","author":"Holder","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.bcp.2026.117889_b0055","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211743","article-title":"MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer","volume":"220","author":"Bhin","year":"2023","journal-title":"J. Exp. Med."},{"issue":"13","key":"10.1016\/j.bcp.2026.117889_b0060","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"JNCI: J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.bcp.2026.117889_b0065","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1021\/acs.jproteome.4c00694","article-title":"Proteomic analysis of microsomal proteins reveals that MVP is crucial for the secretion of GDF-15, which in turn promotes the neuroendocrine differentiation of PCa cells","volume":"23","author":"Pampana","year":"2024","journal-title":"J. Proteome Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117889_b0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058089","article-title":"Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer","volume":"8","author":"Bradshaw-Pierce","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bcp.2026.117889_b0075","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1535-7163.MCT-10-0792","article-title":"Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens","volume":"10","author":"Rivera","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.117889_b0080","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.18632\/oncotarget.23795","article-title":"Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-\u03b2 receptor type I inhibitor","volume":"9","author":"Yingling","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bcp.2026.117889_b0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/0973-029X.84482","article-title":"A study to evaluate the efficacy of xylene-free hematoxylin and eosin staining procedure as compared to the conventional hematoxylin and eosin staining: an experimental study","volume":"15","author":"Ankle","year":"2011","journal-title":"J. Oral Maxillofacial Pathol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117889_b0090","doi-asserted-by":"crossref","first-page":"10898","DOI":"10.1038\/s41598-019-45319-4","article-title":"Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models","volume":"9","author":"Kuo","year":"2019","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2026.117889_b0095","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-11-0085","article-title":"mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling","volume":"1","author":"Rodrik-Outmezguine","year":"2011","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.bcp.2026.117889_b0100","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13435","volume":"56","author":"Tang","year":"2023","journal-title":"Cell Prolif."},{"issue":"12","key":"10.1016\/j.bcp.2026.117889_b0105","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.tibs.2013.10.001","article-title":"Signaling interplay between transforming growth factor-\u03b2 receptor and PI3K\/AKT pathways in cancer","volume":"38","author":"Zhang","year":"2013","journal-title":"Trends Biochem. Sci"},{"issue":"11","key":"10.1016\/j.bcp.2026.117889_b0110","doi-asserted-by":"crossref","first-page":"10870","DOI":"10.1074\/jbc.M413223200","article-title":"Type I transforming growth factor \u03b2 receptor binds to and activates phosphatidylinositol 3-kinase","volume":"280","author":"Yi","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2026.117889_b0115","doi-asserted-by":"crossref","first-page":"H2211","DOI":"10.1152\/ajpheart.00966.2011","article-title":"TGF-\u03b2 and Smad3 modulate PI3K\/Akt signaling pathway in vascular smooth muscle cells","volume":"302","author":"Suwanabol","year":"2012","journal-title":"Am. J. Physiol. Heart Circulat. Physiol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117889_b0120","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2853","article-title":"TGF\u03b2 signalling: a complex web in cancer progression","volume":"10","author":"Ikushima","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bcp.2026.117889_b0125","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2026.117889_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.786728","article-title":"TGF-\u03b2 signaling and resistance to cancer therapy","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117889_b0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1083\/jcb.200611146","article-title":"Cell size and invasion in TGF-\u03b2\u2013induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway","volume":"178","author":"Lamouille","year":"2007","journal-title":"J. Cell Biol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117889_b0140","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/path.2834","article-title":"PMEPA1 promotes androgen receptor\u2010negative prostate cell proliferation through suppressing the Smad3\/4\u2013c\u2010Myc\u2013p21^\\rmCip1 signaling pathway","volume":"223","author":"Liu","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.bcp.2026.117889_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1298660","article-title":"Prostate transmembrane androgen inducible protein 1 (PMEPA1): regulation and clinical implications","volume":"13","author":"Zhu","year":"2023","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.117889_b0150","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41388-019-1050-9","article-title":"PMEPA1 isoform a drives progression of glioblastoma by promoting protein degradation of the Hippo pathway kinase LATS1","volume":"39","author":"Ji","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.117889_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705086","article-title":"PMEPA1 is a prognostic biomarker that correlates with cell malignancy and the tumor microenvironment in bladder cancer","volume":"12","author":"Qiu","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117889_b0160","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3233\/CBM-200966","article-title":"PMEPA1 facilitates non-small cell lung cancer progression via activating the JNK signaling pathway","volume":"31","author":"Tan","year":"2021","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.bcp.2026.117889_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2023.101931","article-title":"Exploring the role of PMEPA1 in gastric cancer","volume":"72","author":"Wen","year":"2023","journal-title":"Mol. Cell. Probes"},{"issue":"4","key":"10.1016\/j.bcp.2026.117889_b0170","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.bbrc.2020.08.012","article-title":"Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells","volume":"531","author":"Watanabe","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.bcp.2026.117889_b0175","first-page":"1568","article-title":"PMEPA1, a transforming growth factor-\u03b2-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer","volume":"63","author":"Brunschwig","year":"2003","journal-title":"Cancer Res."},{"issue":"25","key":"10.1016\/j.bcp.2026.117889_b0180","doi-asserted-by":"crossref","first-page":"21614","DOI":"10.18632\/oncotarget.4308","article-title":"Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients","volume":"6","author":"Serova","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.bcp.2026.117889_b0185","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s13402-014-0210-8","article-title":"Anti-tumor activity of the TGF-\u03b2 receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts","volume":"38","author":"Maier","year":"2015","journal-title":"Cell. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.117889_b0190","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/bcr3039","article-title":"Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer","volume":"13","author":"Miller","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.117889_b0195","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor\u2013positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.117889_b0200","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/bcr3634","article-title":"Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer","volume":"16","author":"Singh","year":"2014","journal-title":"Breast Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.117889_b0205","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10549-017-4375-5","article-title":"A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer","volume":"165","author":"Rugo","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"issue":"12","key":"10.1016\/j.bcp.2026.117889_b0210","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/cancers16122259","article-title":"Resistance to targeted inhibitors of the PI3K\/AKT\/mTOR pathway in advanced oestrogen-receptor-positive breast cancer","volume":"16","author":"Browne","year":"2024","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.bcp.2026.117889_b0215","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1158\/1078-0432.CCR-15-0180","article-title":"A phase I trial of combined ridaforolimus and MK-2206 in patients with advanced malignancies","volume":"21","author":"Gupta","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.117889_b0220","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41388-018-0479-6","article-title":"mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer","volume":"38","author":"Liang","year":"2019","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bcp.2026.117889_b0225","first-page":"1233","article-title":"Interleukin-2 differentially affects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line in vitro and in vivo","volume":"8","author":"Paciotti","year":"1988","journal-title":"Anticancer Res."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2026.117889_b0230","doi-asserted-by":"crossref","first-page":"134","DOI":"10.18632\/genesandcancer.194","article-title":"Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-\u03b2 from growth suppressor to growth and metastasis promoter through TMEPAI\/PMEPA1 in triple negative breast cancer","volume":"10","author":"Singha","year":"2019","journal-title":"Genes Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.117889_b0235","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/bcr43","article-title":"Transforming growth factor-\u03b2 and breast cancer: cell cycle arrest by transforming growth factor-\u03b2 and its disruption in cancer","volume":"2","author":"Donovan","year":"2000","journal-title":"Breast Cancer Res."},{"issue":"9\u201310","key":"10.1016\/j.bcp.2026.117889_b0240","doi-asserted-by":"crossref","first-page":"320","DOI":"10.18632\/genesandcancer.30","article-title":"TGF-\u03b2 induced TMEPAI\/PMEPA1 inhibits canonical Smad signaling through R-Smad sequestration and promotes non-canonical PI3K\/Akt signaling by reducing PTEN in triple negative breast cancer","volume":"5","author":"Singha","year":"2014","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bcp.2026.117889_b0245","unstructured":"A. Varghese, E. Borazanci, D.-Y. Oh, D. Melisi, E. Calvo, A. Hollebecque, T. Macarulla Mercad\u00e9, Safety and activity of the TGF\u03b2 receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer, (2021)."},{"issue":"1","key":"10.1016\/j.bcp.2026.117889_b0250","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s12885-023-11153-1","article-title":"A phase Ib\/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer","volume":"23","author":"Nadal","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117889_b0255","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1476-4598-12-171","article-title":"Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: molecular mechanisms","volume":"12","author":"Kumar","year":"2013","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.117889_b0260","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat. Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:19:49Z","timestamp":1778710789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226002224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"alternative-id":["S0006295226002224"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117889","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PMEPA1 promotes mTOR inhibitor resistance in triple-negative breast cancer: Targeting the TGF-\u03b2\/PMEPA1 axis as a therapeutic strategy to overcome resistance","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117889"}}